GET TOP RATED STOCK ALERTS ACTIVE TRADERS DEPEND ON
SIGN UP TODAY FOR FREE NEWS DRIVEN ALERTS
SEATTLE, WA – October 10, 2018 — Empower Clinics Inc. (OTC: EPWCF; CSE: EPW; FRA 8EC), a leading owner and operator of medical cannabis and wellness clinics in the US, today announced a comprehensive agreement with Titration Technologies, LLC, an innovator in cannabis product development, to manufacture, package, and fulfill Empower’s “Sollievo” CBD medical cannabis products throughout North America.
Empower’s “Sollievo” (Italian for “relief”) products specifically target the most common qualifying medical conditions, involving pain, sleep, stress, and digestion. The products, available as tinctures or topical creams, are non-THC CBD, meaning that they are non-psychotropic: they do not directly affect mood, perception, or consciousness.
As part of the agreement, Titration will produce Empower-formulated CBD medical cannabis products, which Empower will sell under its “Sollievo” product brand on Empower’s Website, at Empower clinics, as well as select third-party wellness clinics throughout the US and Canada. The products will be available at www.empowerclinics.com in the coming weeks.
“This agreement enables patients in all 50 states and Canada to access Empower’s CBD products, which is an important milestone as we continue to expand our business and service areas,” said Craig Snyder, Empower CEO. “As we grow our footprint of medical cannabis and wellness clinics, product sales are an important market channel and revenue stream for us. We are excited to be working with a proven leader like Titration and their team of respected plant scientists.”
Under the agreement, Titration will provide product manufacturing, packaging, warehousing, and fulfillment for Empower.
“Empower has been rapidly building its business and we are looking forward to working with them in providing a superior line of CBD products,” said Jason Sonchik, Titration Director of Quality Control.
ABOUT EMPOWER
Empower is a leading owner and operator of medical cannabis and wellness clinics, as well as a developer of medical products in the US, focused on enabling individuals to improve and protect their health. The company provides treatment solutions through its physician-staffed clinics that are focused on education, data, and efficacy. Empower is a recognized leader and the first choice for patients seeking quality experience and improved health.
For further information about Empower please see the Company’s website at empowerclinics.com.
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events and are therefore based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.
Neither the Canadian Securities Exchange nor the Frankfurt Stock Exchange accepts responsibility for the adequacy or accuracy of this release.
CONTACTS:
Investors:
Steve Low
Boom Capital Markets
647-620-5101
Press:
Mark Peterson
206-390-0204
Source: Empower Clinics Inc.
SEATTLE–(October 1, 2018)– Empower Clinics Inc. (OTC: EPWCF) (CSE: EPW) (FRA 8EC), a leading owner and operator of medical cannabis and wellness clinics in the US, today issued a statement regarding the US Department of Justice and Drug Enforcement Agency’s (DEA) decision late last week to place a cannabidiol (CBD)-based treatment, Epidiolex, in schedule V of the Controlled Substances Act (CSA), the least restrictive schedule of the CSA.
In June, the Food and Drug Administration (FDA) announced that it approved Epidiolex for treating two severe form of epilepsy. Epidiolex is the first FDA-approved drug to contain CBD.
“We are very encouraged by this move, as we believe it will set the stage for potentially more Federally approved medications with CBD,” said Craig Snyder, Empower CEO. “We are prepared to launch our company’s own base of branded CBD products in the very near future and are pleased to see a greater openness at both state and Federal levels to the considerable benefits associated with CBD.”
According to Snyder, Empower’s products will specifically target common medical conditions involving pain, sleep, stress, and digestion. The products, to be available as tinctures or topical creams, are non-THC CBD, meaning that they are non-psychotropic: they do not directly affect mood, perception, or consciousness.
ABOUT EMPOWER
Empower is a leading owner and operator of medical cannabis and wellness clinics, as well as a developer of medical products in the US, focused on enabling individuals to improve and protect their health. The company provides treatment solutions through its physician-staffed clinics that are focused on education, data, and efficacy. Empower is a recognized leader and the first choice for patients seeking quality experience and improved health.
For further information about Empower please see the Company’s website at empowerclinics.com.
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. Forward-looking information contained in this news release includes, but is not limited to, the delisting of the Common Shares from the TSXV, the listing of the Common Shares on the CSE and the future growth plans of the Company. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events and are therefore based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.
Neither the TSXV, the CSE nor their Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
For Empower Clinics Inc.
Investors:
Boom Capital Markets
Steve Low, 647-620-5101
steve@boomcapitalmarkets.com
or
Press:
Mark Peterson, 206-390-0204
Mark@pointerpr.com
Source: Empower Clinics Inc.
Sign Up for FREE
Stock Alerts from
to be the first to know when this emerging company issues Breaking News!
About Empower Clinics
EMPOWERING INDIVIDUALS. IMPROVING HEALTH.
Empower Inc. is a growing network of physician-staffed health clinics focused on helping patients improve and protect their health. Our mission is centered around physician-guided treatment for the relief of chemo-therapy side-effects, seizures, PTSD, and a multitude of chronic pain conditions. We understand that each patient is unique, and we’re here to provide personalized guidance toward the optimal product for their individual need.
OUR DOCTORS
The Empower team of doctors and nurses have a unique breadth and depth in the field of chronic pain managment. Combined they represent over 115 years of medical experience with 40 years of combined medical cannabis experience. Our doctors have attended or served at Harvard, Johns Hopkins, Brown, Baylor, USC, UCLA and Washington University. Our team is passionate about the space and has written over 12 books and published over 300 articles on medical cannabis.
We believe the tenure and experience our doctors possess in treating medical cannabis patients is unique and provides Empower patients the most informed perspective on cannabis education and allows patients to achieve the most impactful efficacy in their treatment.
We’re not here to ‘hand out’ medical marijuana cards. We’re here to have real conversations with real people and get them the appropriate help they need.
DR. JACK MCCUE, MD. FACP AGSF
A graduate of Harvard University and Case Western Reserve University Schools of Medicine, Dr. McCue did his residency training at Johns Hopkins and Harvard in internal medicine and geriatrics. He has traveled the world and worked with patients and other medical professionals in a science-based blending of traditional medical treatment and appropriate use of cannabis. As a distinguished and award-winning physician, Dr. McCue has written 14 books and over 300 articles, in addition to speaking internationally at conferences on many topics including the informed use of medical cannabis.
Since 2014 Dr. McCue has listened to and learned from thousands of patients who have described their personal medical experiences with cannabis. “My typical patient is 50+ year old man with pain. More than 15% of my patients are over 70 years of age. Nearly every one of them is trying to avoid or stop opiates or sleeping pills, and many have serious illnesses that have not responded well to traditional medical therapy.” He believes in the evidence-based use of phytocannabinoids for palliation and in some cases disease treatment, and emphasizes the compatibility of cannabis with modern medical treatments for most symptoms and many illnesses.
DR. LEORA BRITVAN, MD.
Dr. Britvan is a board certified internal medicine physician. She studied medicine at University of Southern California Medical School and trained at Harbor- UCLA for internal medicine. Most of her professional career includes working as a Hospitalist in both California and Oregon for the past twenty years–caring for patients from admission in the emergency room to stay in hospital. She has been evaluating patients for medical cannabis treatment since 2015 and her passion is relieving chronic pain with out the use of narcotics.
DR. DAVID DODGE, MD.
Dr. Dodge is a retired pathologist and nuclear medicine doctor in Portland, Oregon. He received his medical degree from Washington University School of Medicine in St. Louis and served as staff pathologist at Providence Medical Center for more than 20 years. He has helped Oregon cannabis patients at Empower Clinics since 2003.
Dr. Dodge uses medical cannabis to treat his own advanced osteoarthritic pain.
DR. SHAUN HEDMANN, MD.
Dr. Hedmann completed his medical training at Johns Hopkins in Baltimore MD, Baylor in Houston TX and Brown University in Providence RI and before accepting a position with Kaiser Permanente where he practiced Cardiology for 25 years. He has been involved with patients and their need for medical cannabis for nearly 6 years and appreciates the depth and breadth of debilitating conditions that impact their lives.
Individuals incapacitated by medical conditions or the excess of prescribed medications have their lives significantly improved by the judicious use of medical cannabis. He feels profoundly gratified to be able to assist medical cannabis patients to achieve their correct license and also offer insights and suggestions on options for cannabis preparations tailored to their specific medicinal needs.
DR. DAVID LEMMON, ND.
Dr. David Lemmon is a Naturopathic Physician with expertise in natural, nutritional, and plant-based medicine. He received his Doctorate from the National College of Natural Medicine in Portland, Oregon. He has been studying the benefits and uses of medicinal plants including Cannabis for over 15 years. Dr. Lemmon lives Oregon and serves patients in both Oregon and Washington and encourages them to connect to the healing power of nature, and never give up hope in feeling better.
EVELYN KOCHANOWSKI, R.N.
Evelyn has been a RN for 45 yrs. She worked in hospital, clinic and the private home settings, practicing home health, hospice, and post-op nursing. She also practiced as a Nurse Practioner in reproductive care and worked as a nurse in geriatric facilities.
She spent time with the indigenous population in migrant health clinics in the Northwest, Guatemala and Standing Rock reservation. The last 8 years she worked qualifying medical cannabis patients with Empower Clinic.
INVESTOR RELATIONS
For any and all general questions pertaining to investment opportunities and questions, please contact us below and we’ll respond as quickly as possible.
- PR inquiries – please contact Mark Peterson at mark@pointerpr.com
- IR inquires – please contact Steve Low at steve@boomcapitalmarkets.com
- Legal inquiries – please contact Chitiz Pathak at info@chitizpathak.com
- Accounting inquiries – please contact MNP at info@mnp.ca
- Transfer Agent inquires – please contact Computershare at 604.661.9400
Source: https://www.empowerclinics.com/
Disclaimer
FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG’s intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company’s publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated forty six hundred dollars forEmpower Clinics Inc.current news coverage by a non-affiliated third party. FNMG HOLDS NO SHARES OF Empower Clinics Inc.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.